Although we discovered the SLC3A2-NRG1 fusion in a pan-negative lung adenocarcinoma detected by conventional Sanger sequencing, we performed targeted cancer panel deep sequencing to identify possible coexistence with known mutations. This evidence concerns the gene SLC3A2 and lung adenocarcinoma.